{"id":7341,"date":"2021-10-22T13:18:56","date_gmt":"2021-10-22T12:18:56","guid":{"rendered":"https:\/\/www.thervacb.eu\/patienten-2\/die-klinische-thervacb-studie\/"},"modified":"2025-07-15T08:15:33","modified_gmt":"2025-07-15T07:15:33","slug":"die-klinische-thervacb-studie","status":"publish","type":"page","link":"https:\/\/www.thervacb.eu\/de\/patienten\/die-klinische-thervacb-studie\/","title":{"rendered":"Die klinische TherVacB-Studie"},"content":{"rendered":"

[et_pb_section fb_built=“1″ fullwidth=“on“ admin_label=“Section“ _builder_version=“4.16″ da_disable_devices=“off|off|off“ global_colors_info=“{}“ da_is_popup=“off“ da_exit_intent=“off“ da_has_close=“on“ da_alt_close=“off“ da_dark_close=“off“ da_not_modal=“on“ da_is_singular=“off“ da_with_loader=“off“ da_has_shadow=“on“][et_pb_fullwidth_slider use_text_overlay=“on“ text_overlay_color=“rgba(6,66,58,0.25)“ _builder_version=“4.16″ custom_padding=“83px||65px|||“ auto=“on“ auto_ignore_hover=“on“ global_colors_info=“{}“][et_pb_slide heading=“Patienten“ use_bg_overlay=“off“ use_text_overlay=“on“ arrows_custom_color=“#2d788c“ dot_nav_custom_color=“#2d788c“ text_border_radius=“10px“ _builder_version=“4.16″ header_font=“|700|||||||“ header_text_align=“center“ body_text_align=“center“ body_font_size=“30px“ background_enable_color=“off“ use_background_color_gradient=“on“ background_color_gradient_direction=“90deg“ background_color_gradient_stops=“rgba(0,0,0,0) 0%|rgba(0,0,0,0) 100%“ background_color_gradient_overlays_image=“on“ background_color_gradient_start=“rgba(0,0,0,0)“ background_color_gradient_end=“rgba(0,0,0,0)“ background_image=“https:\/\/www.thervacb.eu\/wp-content\/uploads\/the-thervacb-hlinical-study-h.jpg“ background_enable_image=“on“ text_orientation=“center“ header_text_shadow_style=“preset1″ header_text_shadow_color=“#706f6f“ body_text_shadow_style=“preset1″ body_text_shadow_color=“#706f6f“ text_shadow_style=“preset1″ text_shadow_color=“#706f6f“ global_colors_info=“{}“ sticky_transition=“on“]Die klinische TherVacB-Studie[\/et_pb_slide][\/et_pb_fullwidth_slider][\/et_pb_section][et_pb_section fb_built=“1″ admin_label=“Section“ module_id=“Studie“ _builder_version=“4.16″ da_popup_slug=“study“ da_disable_devices=“off|off|off“ global_colors_info=“{}“ da_is_popup=“off“ da_exit_intent=“off“ da_has_close=“on“ da_alt_close=“off“ da_dark_close=“off“ da_not_modal=“on“ da_is_singular=“off“ da_with_loader=“off“ da_has_shadow=“on“][et_pb_row module_id=“approach“ _builder_version=“4.16″ global_colors_info=“{}“][et_pb_column type=“4_4″ _builder_version=“4.16″ global_colors_info=“{}“][et_pb_text _builder_version=“4.16″ global_colors_info=“{}“]<\/p>\n

Kann ich als Hepatitis-B-Patient an der klinischen Studie TherVacB mitwirken \/ teilnehmen?<\/strong><\/h1>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=“1_2,1_2″ admin_label=“map“ _builder_version=“4.16″ _module_preset=“default“ custom_padding=“5px|||||“ global_colors_info=“{}“][et_pb_column type=“1_2″ _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“][et_pb_text _builder_version=“4.25.0″ global_colors_info=“{}“]<\/p>\n

Menschen mit virologischen und gastrointestinalen Parametern, die die Einschlusskriterien erf\u00fcllen, k\u00f6nnen an der klinischen Studie teilnehmen, in die etwa 59 Menschen in Europa und 22 in Afrika aufgenommen werden k\u00f6nnen.<\/p>\n

In dieser klinischen Studie sollen Modifikationen des Hepatitis-B-Impfstoffs TherVacB auf Sicherheit und Vertr\u00e4glichkeit getestet und verglichen werden, um die optimale Wirksamkeit bei Patienten zu definieren.<\/p>\n

Unsere TherVacB-Studienzentren in ganz Europa und im \u00f6stlichen Afrika verf\u00fcgen \u00fcber langj\u00e4hrige Erfahrung in der klinischen Hepatitis-B-Forschung und im Service. Die \u00c4rzte der TherVacB-Studie sind Experten in der Behandlung von viraler Hepatitis.<\/p>\n

<\/span><\/span><\/span><\/p>\n

[\/et_pb_text][et_pb_text _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“]<\/p>\n

Wenn Sie an einer Teilnahme an der klinischen Studie TherVacB interessiert sind, kontaktieren Sie uns<\/a> bitte. Markieren Sie einfach das Kontrollk\u00e4stchen und wir werden uns bei Ihnen melden.<\/p>\n

Es gibt eine ganze Reihe weiterer laufender Studien zu Wirkstoffen in der Entwicklung f\u00fcr die Heilung von chronischer Hepatitis B und HBV. Wenn Sie interessiert sind, finden Sie hier<\/a> weitere Details.<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=“1_2″ _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“][et_pb_map_extended address=“Munich, Germany“ zoom_level=“2″ address_lat=“33.041912795694″ address_lng=“21.337839875″ mobile_dragging=“off“ marker_center=“off“ info_window_width=“250px“ info_window_method=“mouseover“ bounce_on_click_on_off=“on“ marker_animation=“on“ map_type=“4″ map_options=“72″ _builder_version=“4.25.0″ _module_preset=“default“ custom_padding=“30px||30px||false|false“ global_colors_info=“{}“ height__hover_enabled=“on|desktop“ min_height__hover_enabled=“on|desktop“][et_pb_map_pin_extended title=“UNIVERSIT\u00c4T LEIPZIG“ pin_address=“Leipzig, Germany“ pin_address_lat=“51.3396955″ pin_address_lng=“12.3730747″ marker_url=“https:\/\/www.thervacb.eu\/team\/partner-ulei\/“ pin_fill_color=“#5CBDD9″ pin_stroke_color=“#BDBDBD“ pin_circle_color=“#FFFFFF“ _builder_version=“4.9.0″ _module_preset=“default“ global_colors_info=“{}“][\/et_pb_map_pin_extended][et_pb_map_pin_extended title=“ROYAL FREE LONDON NHS FOUNDATION TRUST“ pin_address=“Pond St, Hampstead, London NW3 2QG, UK“ pin_address_lat=“51.5539482″ pin_address_lng=“-0.165902″ marker_url=“https:\/\/www.thervacb.eu\/team\/partner-rfh\/“ pin_fill_color=“#5CBDD9″ pin_stroke_color=“#BDBDBD“ pin_circle_color=“#FFFFFF“ _builder_version=“4.9.0″ _module_preset=“default“ global_colors_info=“{}“][\/et_pb_map_pin_extended][et_pb_map_pin_extended title=“Klinikum Rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen“ pin_address=“Ismaninger Str. 22, 81675 M\u00fcnchen, Germany“ pin_address_lat=“48.136766″ pin_address_lng=“11.5993658″ marker_url=“https:\/\/www.thervacb.eu\/team\/partner-tum-med\/“ pin_fill_color=“#5CBDD9″ pin_stroke_color=“#BDBDBD“ pin_circle_color=“#FFFFFF“ _builder_version=“4.9.0″ _module_preset=“default“ global_colors_info=“{}“][\/et_pb_map_pin_extended][et_pb_map_pin_extended title=“Azienda Ospedaliero- Universitaria di Parma“ pin_address=“Viale Antonio Gramsci, 14, 43126 Parma PR, Italy“ pin_address_lat=“44.8040388″ pin_address_lng=“10.3093369″ marker_url=“https:\/\/www.thervacb.eu\/team\/partner-aop\/“ pin_fill_color=“#5CBDD9″ pin_stroke_color=“#BDBDBD“ pin_circle_color=“#FFFFFF“ _builder_version=“4.9.0″ _module_preset=“default“ global_colors_info=“{}“][\/et_pb_map_pin_extended][et_pb_map_pin_extended title=“Universit\u00e4tsklinikum Hamburg-Eppendorf“ pin_address=“Martinistra\u00dfe 52, 20251 Hamburg, Germany“ pin_address_lat=“53.5918014″ pin_address_lng=“9.9734646″ marker_url=“https:\/\/www.thervacb.eu\/team\/partner-uke\/“ pin_fill_color=“#5CBDD9″ pin_stroke_color=“#BDBDBD“ pin_circle_color=“#FFFFFF“ _builder_version=“4.9.0″ _module_preset=“default“ global_colors_info=“{}“][\/et_pb_map_pin_extended][et_pb_map_pin_extended title=“Fundaci\u00f3 Cl\u00ednic per a la Recerca Biom\u00e8dica “ pin_address=“Carrer del Rossell\u00f3, 149, 08036 Barcelona, Spain“ pin_address_lat=“41.3885916″ pin_address_lng=“2.150884″ marker_url=“https:\/\/www.thervacb.eu\/team\/partner-fcrb\/“ pin_fill_color=“#5CBDD9″ pin_stroke_color=“#BDBDBD“ pin_circle_color=“#FFFFFF“ _builder_version=“4.9.0″ _module_preset=“default“ global_colors_info=“{}“][\/et_pb_map_pin_extended][et_pb_map_pin_extended title=“Barts Health NHS Trust“ pin_address=“Whitechapel Rd, Whitechapel, London E1 1FR, UK“ pin_address_lat=“51.5182221″ pin_address_lng=“-0.0585176″ marker_url=“https:\/\/www.thervacb.eu\/team\/partner-blt\/“ pin_fill_color=“#5CBDD9″ pin_stroke_color=“#BDBDBD“ pin_circle_color=“#FFFFFF“ _builder_version=“4.9.0″ _module_preset=“default“ global_colors_info=“{}“][\/et_pb_map_pin_extended][et_pb_map_pin_extended title=“Medizinische Hochschule Hannover“ pin_address=“Carl-Neuberg-Stra\u00dfe 1, 30625 Hannover, Germany“ pin_address_lat=“52.3845494″ pin_address_lng=“9.8041333″ marker_url=“https:\/\/www.thervacb.eu\/team\/partner-mhh\/“ pin_fill_color=“#5CBDD9″ pin_stroke_color=“#BDBDBD“ pin_circle_color=“#FFFFFF“ _builder_version=“4.9.0″ _module_preset=“default“ global_colors_info=“{}“][\/et_pb_map_pin_extended][et_pb_map_pin_extended title=“NIMR-Mbeya Medizinisches Forschungszentrum“ pin_address=“Hospital Hill Rd, Mbeya, Tanzania“ pin_address_lat=“-8.8892372″ pin_address_lng=“33.4397813″ marker_url=“https:\/\/www.thervacb.eu\/team\/partner-nimr\/“ pin_fill_color=“#5CBDD9″ pin_stroke_color=“#BDBDBD“ pin_circle_color=“#FFFFFF“ _builder_version=“4.9.0″ _module_preset=“default“ global_colors_info=“{}“][\/et_pb_map_pin_extended][et_pb_map_pin_extended title=“LMU – Institut f\u00fcr Infektionskrankheiten und Tropenmedizin“ pin_address=“Leopoldstra\u00dfe 5, 80802 M\u00fcnchen, Deutschland“ pin_address_lat=“48.1540701″ pin_address_lng=“11.5822625″ marker_url=“https:\/\/www.thervacb.eu\/team\/partner-lmu\/“ pin_fill_color=“#5CBDD9″ pin_stroke_color=“#BDBDBD“ pin_circle_color=“#FFFFFF“ _builder_version=“4.25.0″ _module_preset=“default“ global_colors_info=“{}“][\/et_pb_map_pin_extended][et_pb_map_pin_extended title=“Universit\u00e4tsklinikum Frankfurt“ pin_address=“Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Deutschland“ pin_address_lat=“50.095683″ pin_address_lng=“8.6595022″ pin_fill_color=“#5CBDD9″ pin_stroke_color=“#BDBDBD“ pin_circle_color=“#FFFFFF“ _builder_version=“4.25.0″ _module_preset=“default“ global_colors_info=“{}“]<\/p>\n

\"Universit\u00e4tsklinikum<\/a<\/a><\/p>\n

[\/et_pb_map_pin_extended][\/et_pb_map_extended][\/et_pb_column][\/et_pb_row][et_pb_row module_id=“start“ _builder_version=“4.16″ global_colors_info=“{}“][et_pb_column type=“4_4″ _builder_version=“4.16″ global_colors_info=“{}“][et_pb_text _builder_version=“4.25.0″ custom_padding=“||1px|||“ hover_enabled=“0″ global_colors_info=“{}“ sticky_enabled=“0″]<\/p>\n

Wann hat die klinische Studie begonnen?<\/strong><\/h1>\n

Die klinische Studie TherVacB wurde im Juni 2025 begonnen. Dies ist ein wichtiger Meilenstein in unserer Mission, einen kurativen immuntherapeutischen Ansatz f\u00fcr chronische Hepatitis B zu entwickeln. <\/p>\n

Die Studie nimmt derzeit Patienten an mehreren klinischen Standorten in Deutschland auf und wird kontinuierlich auf internationale Studienzentren in Spanien, Italien, Gro\u00dfbritannien und Tansania ausgeweitet. Als Teilnehmer kommen Personen mit chronischer Hepatitis B in Frage, die sich einer antiviralen Standardtherapie unterziehen und zus\u00e4tzliche Einschlusskriterien erf\u00fcllen. <\/p>\n

Weitere Informationen \u00fcber das Studiendesign und die Zulassungskriterien finden Sie bei der Registrierung der klinischen Studie: NCT06513286<\/a>.<\/p>\n

Um mehr \u00fcber die Phasen der klinischen HBV-Studien zu erfahren, sehen Sie sich das folgende Video aus der Reihe „HBV Cure FAQ – Alles, was Sie wissen m\u00fcssen, um die HBV-Forschung zu verstehen“ an .<\/a><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=“1_2,1_2″ _builder_version=“4.23.4″ _module_preset=“default“ custom_margin=“0px||||false|false“ custom_padding=“0px||||false|false“ global_colors_info=“{}“][et_pb_column type=“1_2″ _builder_version=“4.23.4″ _module_preset=“default“ global_colors_info=“{}“][et_pb_video src=“https:\/\/www.youtube.com\/watch?v=NUhNaOAy1-8″ _builder_version=“4.23.4″ _module_preset=“default“ global_colors_info=“{}“][\/et_pb_video][\/et_pb_column][et_pb_column type=“1_2″ _builder_version=“4.23.4″ _module_preset=“default“ global_colors_info=“{}“][et_pb_text _builder_version=“4.23.4″ _module_preset=“default“ global_colors_info=“{}“][\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

Die klinische TherVacB-StudieKann ich als Hepatitis-B-Patient an der klinischen Studie TherVacB mitwirken \/ teilnehmen?Menschen mit virologischen und gastrointestinalen Parametern, die die Einschlusskriterien erf\u00fcllen, k\u00f6nnen an der klinischen Studie teilnehmen, in die etwa 59 Menschen in Europa und 22 in Afrika aufgenommen werden k\u00f6nnen. In dieser klinischen Studie sollen Modifikationen des Hepatitis-B-Impfstoffs TherVacB auf Sicherheit und […]<\/p>\n","protected":false},"author":4,"featured_media":4875,"parent":7338,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-7341","page","type-page","status-publish","has-post-thumbnail","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.thervacb.eu\/de\/wp-json\/wp\/v2\/pages\/7341","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.thervacb.eu\/de\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.thervacb.eu\/de\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.thervacb.eu\/de\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.thervacb.eu\/de\/wp-json\/wp\/v2\/comments?post=7341"}],"version-history":[{"count":32,"href":"https:\/\/www.thervacb.eu\/de\/wp-json\/wp\/v2\/pages\/7341\/revisions"}],"predecessor-version":[{"id":12917,"href":"https:\/\/www.thervacb.eu\/de\/wp-json\/wp\/v2\/pages\/7341\/revisions\/12917"}],"up":[{"embeddable":true,"href":"https:\/\/www.thervacb.eu\/de\/wp-json\/wp\/v2\/pages\/7338"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.thervacb.eu\/de\/wp-json\/wp\/v2\/media\/4875"}],"wp:attachment":[{"href":"https:\/\/www.thervacb.eu\/de\/wp-json\/wp\/v2\/media?parent=7341"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}